2. Academic Validation
  3. IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia

IKZF1 Alterations and Therapeutic Targeting in B-Cell Acute Lymphoblastic Leukemia

  • Biomedicines. 2024 Jan 1;12(1):89. doi: 10.3390/biomedicines12010089.
Jonathan Paolino 1 2,  Harrison K Tsai 3,  Marian H Harris 3,  Yana Pikman 1 2
Affiliations

Affiliations

  • 1 Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
  • 2 Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA 02115, USA.
  • 3 Department of Pathology, Boston Children's Hospital, Boston, MA 02115, USA.
PMID: 38255194 DOI: 10.3390/biomedicines12010089
Abstract

IKZF1 encodes the transcription factor IKAROS, a zinc finger DNA-binding protein with a key role in lymphoid lineage development. IKAROS plays a critical role in the development of lineage-restricted mature lymphocytes. Deletions within IKZF1 in B-cell acute lymphoblastic leukemia (B-ALL) lead to a loss of normal IKAROS function, conferring leukemic stem cell properties, including self-renewal and subsequent uncontrolled growth. IKZF1 deletions are associated with treatment resistance and inferior outcomes. Early identification of IKZF1 deletions in B-ALL may inform the intensification of therapy and Other potential treatment strategies to improve outcomes in this high-risk leukemia.

Keywords

B-cell acute lymphoblastic leukemia; IKAROS; IKZF1.

Figures